Vinorelbine (Navelbine®) in the treatment of non-small-cell lung cancer: Studies with single-agent therapy and in combination with cisplatin

Annals of Oncology

Volumn 10, Issue SUPPL. 5, 1999, Pages

  Gralla, R ^a   Harper, P ^c   Johnson, S ^c   Delgado, F M ^b  

^a OCHSNER CLINIC FOUNDATION   (United States)

^b INSTITUT DE RECHERCHE PIERRE FABRE   (France)

^c NONE

Author keywords

Cisplatin; Non small cell lung cancer; Vinorelbine

Indexed keywords

CISPLATIN; NAVELBINE; VINDESINE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; VINBLASTINE;

ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME; LUNG TUMOR; PATHOLOGY; REVIEW;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; HUMANS; LUNG NEOPLASMS; TREATMENT OUTCOME; VINBLASTINE;

EID: 0032692677     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/10.suppl_5.S41     Document Type: Conference Paper

References (43)

1. Non-Small-Cell Lung Cancer Collaborative Group. Chemotherapy in non-small-cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995; 311: 899-909.
2. Bunn PA. The expanding role of cisplatin in the treatment of non-small-cell lung cancer. Semin Oncol 1992; 16: 10-21.
3. Steward WP, Dunlop DJ. New drugs in the treatment of non-small-cell lung cancer. Ann Oncol 1995; 6 (Suppl 1): S49-54.
4. Rapp E, Pater JL, Willan A et al. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer report of a Canadian multicenter randomized trial. J Clin Oncol 1988; 6: 633-41.
5. Paintrand MR, Pignot I. Navelbine®: An ultrastructure study of its effects. J Electron Microscopy 1983; 32: 115-24.
6. Cros S, Takoudju M, Schaepelynck-Lataste H et al. Comparative in vitro and in vivo study of Navelbine® ditartrate (Nor-5′-anhydrovinblastine) with the two antitumor compounds: Vinblastine and vincristine. In Ishigami J (ed): Recent Advances Chemotherapy. Anticancer, Section 1. Tokyo: University Press 1985; 477-8.
7. Rahmani R, Martin M, Barbet J, Cano JP. Radioimmunoassay and preliminary pharmacokinetic studies in rats of 5′-Noranhydrovinblastine (Navelbine®). Cancer Res 1984; 44: 5609-13.
8. Cros S, Wright M, Morimoto M et al. Experimental antitumour activity of Navelbine. Semin Oncol 1989; 16 (Suppl 4): 15-20.
9. ADAMS DJ. Synergy of Navelbine Taxol combination treatment in two human breast cancer cell lines. Proc Am Assoc Cancer Res 1994; 35: 327.
10. Mathe G, Reizenstein P et al. Phase I pharmacologic study of a new vinca-alkaloid: Navelbine®. Cancer Lett 1985; 27: 285-93.
11. Khayat D, Covelli A, Variol P et al. Phase I and pharmacologic study of intravenous Navelbine® in patients with solid tumors. Proc Am Soc Clin Oncol 1995; 14: 469 (Abstr 1518).
12. Schilling T, Fiebig H, Karpel Fronious S et al. Clincal phase I and pharmacokinetic trial of Navelbine® administered as single intravenous bolus every 21 days in cancer patients. Invest N Drugs 1996; 14: 371-8.
13. Depierre A, Lemarie E, Dabouis G et al. A phase II study of vinorelbine® (vinorelbine) in the treatment of non-small-cell lung cancer. Am J Clin Oncol 1991; 14: 115-9.
14. Crawford J, O'Rourke M, Schiller H et al. Randomised trial with Vinorelbine compared with Fluorouracil plus Leucoverin in patients with stage IV NSCLC. J Clin Oncol 1996; 14: 2774-8.
15. Perrone F, Rossi A, Ianniello GP et al. Vinorelbine plus best supportive care vs. best supportive care in the treatment of advanced non-small-cell lung cancer in elderly patients. Results of a phase III. Proc Am Soc Clin Oncol 1998; 17: A1752.
16. Rinaldi M, Della Giulia M, Ventura P et al. Vinorelbine as single agent in the treatment of advanced non-small-cell lung cancer. Proc Am Soc Clin Oncol 1994; 13: A1212.
17. Crivellari D, Veronesi A, Sacco C et al. Phase II study of vinorelbine in 50 patients with non-small-cell lung cancer. Proc Am Soc Clin Oncol 1994; 13: A1192.
18. Malzyner A, Bruno S, Piris N et al. Randomised phase II trial of vinorelbine vs. NVB + CDDP in patients with inoperable non-small-cell lung cancer. Eur J Cancer 1991; 27: S172 (Abstr 1048).
19. Depierre A, Chastang C, Choix E et al. Vinorelbine versus vinorelbine plus cisplatin in advanced non-small-cell lung cancer: A randomized trial. Ann Oncol 1994; 5: 37-42.
20. Le Chevalier T, Brisgand D, Douillard JY et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: Results of a European multicenter trial including 612 patients. J Clin Oncol 1994; 12: 360-7.
21. Gil Deza E, Balbiani L, Coppola F et al. Phase III study of vinorelbine (NVB) vs. NVB plus cisplatin in non-small-cell lung cancer (NSCLC) stage IIIB or IV. Proc Am Soc Clin Oncol 1996; 15: A1193.
22. Furuse K, Kubota K, Kawahara M et al. A phase II study of vinorelbine, a new derivative of vinca alkaloid, for previously untreated advanced non-small-cell lung cancer. Lung Cancer 1994; 11: 385-91.
23. Verones A, Crivellari D, Magri MD et al. Vinorelbine treatment of advanced non-small-cell lung cancer with special emphasis on elderly patients. Eur J Cancer 1996; 32A: 1809-11.
24. Gridelli C, Perrone F, Gallo C et al. Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small-cell lung cancer. A two-stage phase II study. Eur J Cancer 1997; 33: 392-7
25. Tononi A, Panzini I, Olivero G et al. Vinorelbine chemotherapy in non-small-cell lung cancer: Experience in elderly patients. J Chemother 1997; 9: 304-8.
26. Berthaud P, Le Chevalier T, Ruffie P et al. Phase I-II study of vinorelbine (Vinorelbine) plus cisplatin in advanced non-small-cell lung cancer. Eur J Cancer 1992 ; 28A: 1863-5.
27. Smith TJ, Hillner BE, Neighbors DM et al. Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small-cell lung cancer. J Clin Oncol 1995; 13: 2166-73.
28. Brooks BJ, Gralla RJ, McGraw HJ et al. Cisplatin and vinorelbine (vinorelbine®) combination chemotherapy for advanced non-small-cell lung cancer: Testing the efficacy of a regimen designed to reduce toxicity and increase dose intensity. Proc Am Soc Clin Oncol 1994; 13: A1162.
29. Terrassa J, Rifa J, Garcia-Bueno JM et al. Cisplatin and vinorelbine in advanced non-small-cell lung cancer. Ann Oncol 1996; 7: A461P.
30. De Marinis F, Rimoldi R, Piacenza G et al. Advanced non-small-cell lung cancer: Treatment with cisplatin and two different schedules of vinorelbine. Proc 4th Int Cancer Conf. Perugia 1993; A99.
31. Spironidis CH, Laufman LR, Jones JJ et al. Phase II trial of daily × 4 vinorelbine-cisplatin in advanced non-small-cell lung cancer: A preliminary report. Proc Am Soc Clinc Oncol 1997; 16: A1737.
32. Gebbia V, Caruso M, Valenza R et al. Vinorelbine plus cisplatin for the treatment of stage IIIB and IV non-small-cell lung carcinoma. Anticancer Res 1994; 14 (3B): 1247-9.
33. Jacoulet P, Dubiez A, Depierre A et al. One-week versus three-weeks intervals in the administration of cisplatin in combination with vinorelbine: A randomized study in non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1992; 11: A1013.
34. Priolo D, Panebianco V, Fallica G et al. Vinorelbine and cisplatin: An intriguing reappraisal for chemotherapy in non-small-cell lung cancer. Proc 4th Int Cancer Conf. Perugia 1993; 118.
35. Yamamoto M, Ariyoshi Y, Hasegawa K et al. Phase I clinical study of KW 2307 combined with cisplatin in non-small-cell lung cancer patients. Jpn J Cancer Chemother 1994; 21: 993-9.
36. Piazza E, Filipazzi V, Rho B et al. Cisplatin vinorelbine association chemotherapy in the treatment of locally advanced NSCLC. Proc IASLC 1994; Suppl 1: 128 (Abstr 490).
37. Pawlicki M, Rodrigues J, Firat D et al. An overview of three phase II trials of vinorelbine and fractionated doses of cisplatin in the management of advanced non-small-cell lung cancer. Eur J Cancer 1993; 33 (Suppl 8): A1069; ECCO 1997; 33: S236.
38. Pawlicki M, Rodrigues J, Firat D et al. An overview of three phase II trials of vinorelbine and fractionated doses of cisplatin in the management of advanced non-small-cell lung cancer. Eur J Cancer 1993; 33 (Suppl 8): A1069; ECCO 1997; 33: S236.
39. Cattaneo MT, Candido P, Oriandini B et al. CDDP + NVB association chemotherapy in stage III-IV NSCLC. Results of a phase II study. Eur J Cancer 1995; 31A (Suppl 5): A1093.
40. Goedhals L, Bezwoda W, Vorobiof D et al. Phase II trial of i.v. vinorelbine and cisplatin in inoperable locally advanced or disseminated NSCLC. Eur J Cancer 1997; 33 (Suppl 8): A1082.
41. Wozniak AJ, Crowley JJ, Balcerzak SP et al. Randomized phase III trial of cisplatin vs. CDDP + vinorelbine in treatment of advanced non-small-cell lung cancer: An update of a South West Oncology Group Study (SWOG 9308). Proc Am Soc Clin Oncol 1998; 17: A1744.
42. Gebbia V, Galetta D, Riccardi F et al. Randomized phase II trial of mitomycin plus vindesine and cisplatin versus vinorelbine and cisplatin in stage III-IV non-small-cell lung cancer: A Southern Italy Oncology Group study (GOIM). Lung Cancer 1997; 18 (Suppl 1): A87.
43. Furuse K, Fukuoka M, Kuba M et al. Randomized study of vinorelbine versus vindesine in previously untreated stage IIIB or IV non-small-cell lung cancer. Ann Oncol 1996; 7: 815-40.